Niche pharmacogenomics PharmGKB operates as a specialized pharmacogenomics knowledge resource with clinical dosing guidelines and genotype-phenotype data, presenting a targeted opportunity to upsell premium data access, curated datasets, and integration with clinical decision support tools.

Clinical data interfaces The platform curates genotype and phenotype data and links gene-drug-disease relationships, suggesting sales potential for API access, data feeds, and PHA-compliant integration to streamline hospital and research workflows.

NIH-backed credibility Supported by NIH/NHGRI/NICHD funding, PharmGKB carries strong bioscience credibility, which can be leveraged to position enterprise collaborations, sponsored research, and grant-aligned partnerships with pharma and academic institutions.

Small team agility With a lean team of 2–10 employees, targeted outreach, partnerships, and white-labeling opportunities for pharmacogenomics knowledge integration could yield high value with low operational burden.

Revenue context Current revenue under $1M indicates room for scalable solutions such as enterprise data licenses, custom analytics, and professional services for drug development programs seeking pharmacogenomic insights.